I am a
Home I AM A Search Login

Papers of the Week

Papers: 9 Nov 2019 - 15 Nov 2019

Human Studies

2020 May 01

Pain Med



Limited Access to On-Label Formulations of Buprenorphine for Chronic Pain as Compared with Conventional Opioids.


Fishman MA, Scherer A, Topfer J, Kim PSH
Pain Med. 2020 May 01; 21(5):1005-1009.
PMID: 31697314.


Buprenorphine is a Schedule III analgesic that is recommended as the firstline long-acting opioid for the treatment of chronic pain due to its ceiling effect on respiratory depression, adverse effect profile, and analgesic efficacy. However, prescription drug coverage policies commonly require that patients try and fail multiple Schedule II conventional opioids before approval of on-label use of buprenorphine for chronic pain.